Researchers at the University of Michigan Department of Surgery have begun testing an alternative to embryonic stem cells that could one day regenerate muscle tissue for babies with congenital heart defects. A research-in-progress report on this new approach, which uses amniotic stem cells, was presented today at the 2013 Clinical Congress of the American College of Surgeons. Although this research is still in an early phase, this new approach has the potential to one day help thousands of babies born each year with congenital heart defects.
Typically, a pregnant woman can have a fetal ultrasound performed to find out the sex of her baby between 18 and 20 weeks gestation. But each year during pregnancy or after birth, 40,000 women also find out that their babies have birth defects in their hearts, according to the Centers for Disease Control and Prevention.*
Babies with congenital heart defects often go through multiple heart operations or even a transplant before their first birthday. But Shaun Kunisaki, MD, a pediatric surgeon and assistant professor of surgery at the University of Michigan, and his surgical team are testing a new method of regenerating defective heart tissue so that one day these multiple operations may no longer be necessary.
"We know that the baby's heart cells are functioning, but the muscle has developed abnormally," lead study author Dr. Kunisaki said. "We have to find the right source of new cells to replace the damaged cells or generate new tissue to augment the damaged heart."
Stem Cell Shortfalls
Until now embryonic stem cells have shown potential to morph into various types of organ tissues, but the ethics surrounding the process of having to destroy the embryo to achieve this outcome has drawn controversy.
Stem cells from bone marrow have also seemed promising, but such cells are obviously hard to obtain from a fetus. Furthermore, getting bone marrow from a donor brings about the same risk as having a heart transplant—having to suppress the newborn infant's immune system so that its body doesn't reject the foreign cells. "Also, bone marrow cells are not made to function like heart muscle cells, but rather to protect against inflammation," Dr. Kunisaki explained.
Cardiac stem cells, which are in the heart, have also been considered, but the heart contains a very limited number of these stem cells.
Amniotic stem cells, however, contain the same genetic makeup as the fetus. Therefore, this approach eliminates the possibility of the newborn infant's body rejecting the cells. And these cells are easily obtainable from amniocentesis, a standard prenatal genetic test in which fluid is extracted from the amniotic sac.
Morphing into heart muscle cells
Beginning in the last quarter of 2011, Dr. Kunisaki and his team obtained amniotic fluid samples from eight pregnant women. They extracted a type of cell called mesenchymal stromal cells, which are the most common type of cell in amniotic fluid.
The next step was to transform those cells into induced pluripotent stem cells with the exact genetic makeup of the fetus. This step involved genetically reprogramming the cells to be, similar to embryonic stem cells, flexible enough to morph into any cell in the human body—such as the heart muscle.
"Once you have true stem cells, then you can expose these cells in a culture condition, which favors transformation into a heart cell," Dr. Kunisaki reported.
After three weeks in a culture, Dr. Kunisaki and his team observed the amniotic stem cells transform into heart muscle cells. The team confirmed that the cells were indeed heart cells with an antibody test, which has signature proteins that only bind to certain types of cells—in this case, the newly grown heart cells. "And you could see these cells beating in the culture dish," he added.
Next steps and ultimate goals
In the future, Dr. Kunisaki envisions being able to deliver amniotic stem cells to babies with congenital heart defects soon after delivery. The cells would then begin to regenerate damaged tissue into a healthy heart or could serve to augment heart operations. This treatment could help newborn infants stay alive without a transplant.
"Babies have to rely on mom and the placenta for everything. After they're born, they have to rely on their own hearts to function," Dr. Kunisaki explained. "The ideal situation is to have heart stem cells available when they are born. We diagnose heart defects at about 20 weeks gestation. That timeframe gives five months or so to generate heart cells to use at birth."
The researchers' laboratory process of transforming amniotic fluid cells into beating heart cells took just under 12 weeks. The next step is to move the study to a mouse model, which Dr. Kunisaki estimates will begin in 2014. The ultimate step will be testing the procedure on an actual baby.
"Pregnancy is supposed to be a time to celebrate and welcome a new family member into the world. One of the hardest parts of my job as a surgeon is telling a family that their baby has a heart defect," Dr. Kunisaki said. "Instead, these families have to talk about unforeseen circumstances, such as how to care for a seriously ill child after birth. Often there are not many comforting answers, but our goal is to offer more options."
Explore further: Study shows amniotic fluid stem cells, heart cells pass signals without touching
More information: * Centers for Disease Control and Prevention. Congenital Heart Defects – Data and Statistics. Available at: www.cdc.gov/ncbddd/heartdefects/data.html. Accessed September 6, 2013.
Medical Xpress on facebook
Related Stories
Study shows amniotic fluid stem cells, heart cells pass signals without touching
May 02, 2013
Stem cells drawn from amniotic fluid show promise for tissue engineering, but it's important to know what they can and cannot do. A new study by researchers at Rice University and Texas Children's Hospital ...
Mayo Clinic first in US to test stem cells in pediatric congenital heart disease patients
Jun 11, 2013
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic ...
Heart's own stem cells offer hope for new treatment of heart failure
Aug 15, 2013
Researchers at King's College London have for the first time highlighted the natural regenerative capacity of a group of stem cells that reside in the heart. This new study shows that these cells are responsible ...
Mayo Clinic restores disrupted heartbeat with regenerative intervention
Sep 03, 2013
Mayo Clinic researchers have found a way to resynchronize cardiac motion following a heart attack using stem cells. Scientists implanted engineered stem cells, also known as induced pluripotent stem (iPS) cells, into damaged ...
Scientists identify key regulator controlling formation of blood-forming stem cells
Sep 26, 2013
Stem cell scientists have moved one step closer to producing blood-forming stem cells in a Petri dish by identifying a key regulator controlling their formation in the early embryo, shows research published online today in ...
Recommended for you
Use of beta-blocker helps achieve target heart rate level among patients in septic shock
3 hours ago
Andrea Morelli, M.D., of the University of Rome, Italy, and colleagues conducted a study to investigate the effect of the short-acting beta-blocker esmolol on the heart rate of patients with severe septic shock and high risk ...
New technique enables accurate, hands-free measure of heart and respiration rates
17 hours ago
A simple video camera paired with complex algorithms appears to provide an accurate means to remotely monitor heart and respiration rates day or night, researchers report.
Diabetes: Personalised therapy reduces the risk of cardiovascular disease
Oct 08, 2013
Six-hundred thousand to eight-hundred thousand Austrians suffer from diabetes mellitus. Thanks to the biomarker known as NT-proBNP (a hormone specific to the heart), the sub-group of people who are at increased risk of cardiovascular ...
Health-care providers should aggressively treat unhealthy lifestyles
Oct 07, 2013
Healthcare providers should treat unhealthy behaviors as aggressively as they treat high blood pressure, cholesterol and other heart disease risk factors, according to an American Heart Association policy statement published ...
Pediatric atrial fibrillation, rare, but has serious complications risk and high recurrence rates
Oct 07, 2013
Atrial fibrillation (AF), characterized by a rapid and irregular heartbeat, is the most common chronic arrhythmia in adults, but is rare in children. In one of the first studies of pediatric "lone AF" (AF without associated ...
Team designing new drug for common heart condition
Oct 07, 2013
An international research team led by medical scientists at the University of Alberta has shown that new medications based on resveratrol—a compound found in red wine and nuts—may be used to treat a common heart-rhythm ...
User comments
© Medical Xpress 2011-2013, Phys.org network
Researchers at the University of Michigan Department of Surgery have begun testing an alternative to embryonic stem cells that could one day regenerate muscle tissue for babies with congenital heart defects. A research-in-progress report on this new approach, which uses amniotic stem cells, was presented today at the 2013 Clinical Congress of the American College of Surgeons. Although this research is still in an early phase, this new approach has the potential to one day help thousands of babies born each year with congenital heart defects.
Typically, a pregnant woman can have a fetal ultrasound performed to find out the sex of her baby between 18 and 20 weeks gestation. But each year during pregnancy or after birth, 40,000 women also find out that their babies have birth defects in their hearts, according to the Centers for Disease Control and Prevention.*
Babies with congenital heart defects often go through multiple heart operations or even a transplant before their first birthday. But Shaun Kunisaki, MD, a pediatric surgeon and assistant professor of surgery at the University of Michigan, and his surgical team are testing a new method of regenerating defective heart tissue so that one day these multiple operations may no longer be necessary.
"We know that the baby's heart cells are functioning, but the muscle has developed abnormally," lead study author Dr. Kunisaki said. "We have to find the right source of new cells to replace the damaged cells or generate new tissue to augment the damaged heart."
Stem Cell Shortfalls
Until now embryonic stem cells have shown potential to morph into various types of organ tissues, but the ethics surrounding the process of having to destroy the embryo to achieve this outcome has drawn controversy.
Stem cells from bone marrow have also seemed promising, but such cells are obviously hard to obtain from a fetus. Furthermore, getting bone marrow from a donor brings about the same risk as having a heart transplant—having to suppress the newborn infant's immune system so that its body doesn't reject the foreign cells. "Also, bone marrow cells are not made to function like heart muscle cells, but rather to protect against inflammation," Dr. Kunisaki explained.
Cardiac stem cells, which are in the heart, have also been considered, but the heart contains a very limited number of these stem cells.
Amniotic stem cells, however, contain the same genetic makeup as the fetus. Therefore, this approach eliminates the possibility of the newborn infant's body rejecting the cells. And these cells are easily obtainable from amniocentesis, a standard prenatal genetic test in which fluid is extracted from the amniotic sac.
Morphing into heart muscle cells
Beginning in the last quarter of 2011, Dr. Kunisaki and his team obtained amniotic fluid samples from eight pregnant women. They extracted a type of cell called mesenchymal stromal cells, which are the most common type of cell in amniotic fluid.
The next step was to transform those cells into induced pluripotent stem cells with the exact genetic makeup of the fetus. This step involved genetically reprogramming the cells to be, similar to embryonic stem cells, flexible enough to morph into any cell in the human body—such as the heart muscle.
"Once you have true stem cells, then you can expose these cells in a culture condition, which favors transformation into a heart cell," Dr. Kunisaki reported.
After three weeks in a culture, Dr. Kunisaki and his team observed the amniotic stem cells transform into heart muscle cells. The team confirmed that the cells were indeed heart cells with an antibody test, which has signature proteins that only bind to certain types of cells—in this case, the newly grown heart cells. "And you could see these cells beating in the culture dish," he added.
Next steps and ultimate goals
In the future, Dr. Kunisaki envisions being able to deliver amniotic stem cells to babies with congenital heart defects soon after delivery. The cells would then begin to regenerate damaged tissue into a healthy heart or could serve to augment heart operations. This treatment could help newborn infants stay alive without a transplant.
"Babies have to rely on mom and the placenta for everything. After they're born, they have to rely on their own hearts to function," Dr. Kunisaki explained. "The ideal situation is to have heart stem cells available when they are born. We diagnose heart defects at about 20 weeks gestation. That timeframe gives five months or so to generate heart cells to use at birth."
The researchers' laboratory process of transforming amniotic fluid cells into beating heart cells took just under 12 weeks. The next step is to move the study to a mouse model, which Dr. Kunisaki estimates will begin in 2014. The ultimate step will be testing the procedure on an actual baby.
"Pregnancy is supposed to be a time to celebrate and welcome a new family member into the world. One of the hardest parts of my job as a surgeon is telling a family that their baby has a heart defect," Dr. Kunisaki said. "Instead, these families have to talk about unforeseen circumstances, such as how to care for a seriously ill child after birth. Often there are not many comforting answers, but our goal is to offer more options."
Explore further: Study shows amniotic fluid stem cells, heart cells pass signals without touching
More information: * Centers for Disease Control and Prevention. Congenital Heart Defects – Data and Statistics. Available at: www.cdc.gov/ncbddd/heartdefects/data.html. Accessed September 6, 2013.
Medical Xpress on facebook
Related Stories
Study shows amniotic fluid stem cells, heart cells pass signals without touching
May 02, 2013
Stem cells drawn from amniotic fluid show promise for tissue engineering, but it's important to know what they can and cannot do. A new study by researchers at Rice University and Texas Children's Hospital ...
Mayo Clinic first in US to test stem cells in pediatric congenital heart disease patients
Jun 11, 2013
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic ...
Heart's own stem cells offer hope for new treatment of heart failure
Aug 15, 2013
Researchers at King's College London have for the first time highlighted the natural regenerative capacity of a group of stem cells that reside in the heart. This new study shows that these cells are responsible ...
Mayo Clinic restores disrupted heartbeat with regenerative intervention
Sep 03, 2013
Mayo Clinic researchers have found a way to resynchronize cardiac motion following a heart attack using stem cells. Scientists implanted engineered stem cells, also known as induced pluripotent stem (iPS) cells, into damaged ...
Scientists identify key regulator controlling formation of blood-forming stem cells
Sep 26, 2013
Stem cell scientists have moved one step closer to producing blood-forming stem cells in a Petri dish by identifying a key regulator controlling their formation in the early embryo, shows research published online today in ...
Recommended for you
Use of beta-blocker helps achieve target heart rate level among patients in septic shock
3 hours ago
Andrea Morelli, M.D., of the University of Rome, Italy, and colleagues conducted a study to investigate the effect of the short-acting beta-blocker esmolol on the heart rate of patients with severe septic shock and high risk ...
New technique enables accurate, hands-free measure of heart and respiration rates
17 hours ago
A simple video camera paired with complex algorithms appears to provide an accurate means to remotely monitor heart and respiration rates day or night, researchers report.
Diabetes: Personalised therapy reduces the risk of cardiovascular disease
Oct 08, 2013
Six-hundred thousand to eight-hundred thousand Austrians suffer from diabetes mellitus. Thanks to the biomarker known as NT-proBNP (a hormone specific to the heart), the sub-group of people who are at increased risk of cardiovascular ...
Health-care providers should aggressively treat unhealthy lifestyles
Oct 07, 2013
Healthcare providers should treat unhealthy behaviors as aggressively as they treat high blood pressure, cholesterol and other heart disease risk factors, according to an American Heart Association policy statement published ...
Pediatric atrial fibrillation, rare, but has serious complications risk and high recurrence rates
Oct 07, 2013
Atrial fibrillation (AF), characterized by a rapid and irregular heartbeat, is the most common chronic arrhythmia in adults, but is rare in children. In one of the first studies of pediatric "lone AF" (AF without associated ...
Team designing new drug for common heart condition
Oct 07, 2013
An international research team led by medical scientists at the University of Alberta has shown that new medications based on resveratrol—a compound found in red wine and nuts—may be used to treat a common heart-rhythm ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment